$AVCRF News

HealthTab™ to Expand Across North East London

HealthTab™ to Power NHS Pilot

Avricore Health’s HealthTab™ Platform Expands to North Central London in Groundbreaking NHS Pharmacy-Led Cardiovascular Project

Avricore Grants Options

Avricore Appoints Rodger Seccombe as CEO

AVRICORE HEALTH CORPORATE UPDATE: Q1 Results and Ongoing Progress Report

Avricore Health Full Year 2024 Earnings: CA$0.007 loss per share (vs CA$0.007 loss in FY 2023)

AVRICORE HEALTH CORPORATE UPDATE: 2024 record year, UK expansion on track

Avricore Health Inc. (CVE:AVCR) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

HealthTab™ and Patients Know Best® Bring Pharmacy-Based Blood Test Results to Millions in UK

3 TSX Penny Stocks With Market Caps Below CA$20M

Discover 3 TSX Penny Stocks To Watch In December 2024

Avricore Health Corporate Update: Effective Plan, Resources Result in Success

Avricore Health Refocuses Strategy to Unlock Growth Potential

Avricore Health And 2 Other TSX Penny Stocks To Watch

Avricore Health Recognized in Deloitte’s 2024 Technology Fast 50™ Companies to Watch

Keynotes and 50 Companies to Present at the Planet MicroCap Showcase: VANCOUVER in association with Small Cap Discoveries on September 25-26, 2024 at the Fairmont Waterfront Vancouver

Avricore Health Second Quarter 2024 Earnings: EPS: CA$0.001 (vs CA$0.003 loss in 2Q 2023)

Avricore Grants Options

Avricore Health Corporate Update: Mid-Year Results Show Strong Growth, Profitability